We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
6 own
23 watching
Current Price
$7.13
$0.46
(6.9%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
887.05M
52-Week High
11.69
52-Week Low
2.5
Average Volume
0.47M
Dividend Yield
--
P/E Ratio
--
Market Capitalization887.05M
52-Week High11.69
52-Week Low2.5
Average Volume0.47M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. Its product candidates in pre-clinical development comprise SER-301, a synthetic Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-155, an Ecobiotic microbiome therapeutic for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Business Wire
1month ago
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication of Phase 3 clinical data in the Journal of the American Medical Association (JAMA), highlighting that the clinical benefits of investigational therapeutic SER-109 for preventing...
PR Newswire
1month ago
Alltrna Appoints Caroline Khrer, Ph.D., Vice President, Discovery Platform Alltrna Appoints Caroline Khrer, Ph.D., Vice President, Discovery Platform PR Newswire CAMBRIDGE, Mass., Oct. 17, 2022 Dr. Khrer has more than 25 years of RNA research and development experience, including pioneering novel...
PR Newswire
2 months ago
Thinking about buying stock in Rubius Therapeutics, NextPlat, Seres Therapeutics, Cassava Sciences, or Alaunos Therapeutics? Thinking about buying stock in Rubius Therapeutics, NextPlat, Seres Therapeutics, Cassava Sciences, or Alaunos Therapeutics? PR Newswire NEW YORK, Sept. 23, 2022 NEW YORK...
PR Newswire
5 months ago
Thinking about buying stock in Aprea Therapeutics, Dermata Therapeutics, Seres Therapeutics, Avadel Pharmaceuticals, or Clovis Oncology? Thinking about buying stock in Aprea Therapeutics, Dermata Therapeutics, Seres Therapeutics, Avadel Pharmaceuticals, or Clovis Oncology? PR Newswire NEW YORK...
Globe Newswire
6 months ago
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactionsFormer Global Head of Infectious Diseases for Johnson & Johnson PharmaceuticalsFormer Venture Partner at Flagship Pioneering, as ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$7.13
$0.46
(6.9%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00